Regulus Therapeutics Inc.
San Diego, US · 87,247 employees on LinkedIn · 2 known investors
Founders & leadership
MG
Mark G. FolettaNamed on SEC filing
JM
John MaraganoreNamed on SEC filing
DE
Douglas E. WilliamsNamed on SEC filing
WH
William H. RastetterNamed on SEC filing
DB
David BaltimoreNamed on SEC filing
BL
Bruce L.A. CarterNamed on SEC filing
BL
B. Lynne ParshallNamed on SEC filing
NG
Neil GibsonNamed on SEC filing
SP
Stelios PapadopoulosNamed on SEC filing
KX
Kleanthis XanthopoulosNamed on SEC filing
Investors · 2
Reported raises · per SEC filings
Form D private placements$80.7M disclosed across 4 rounds · 2014–2021
▶$34.6MraisedDec 2021 · 16 investors · PharmaceuticalsRule 506(b)
▶$34.6MraisedDec 2021 · 16 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Joseph HaganExecutive Officer, Director
- Christopher AkerExecutive Officer
- Alice S. HuangDirector
- Cris CalsadaExecutive Officer
- Jake R. NunnDirector
- David BaltimoreDirector
- Denis DryginExecutive Officer
- William H. RastetterDirector
- Pascale WitzDirector
- Kathryn J. CollierDirector
- Stelios PapadopoulosDirector
- Simos SimeonidisDirector
- Hugh RosenDirector
- Offering amount
- $34.6M
- Amount sold
- $34.6M
- Sales commissions
- $2.1M
- Placement agents
- H. C. Wainwright & Co., LLC, SVB Leerink LLC
- First sale
- Nov 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$19.4MraisedDec 2020 · 18 investors · PharmaceuticalsRule 506(b)
▶$19.4MraisedDec 2020 · 18 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Joseph HaganExecutive Officer, Director
- Cris CalsadaExecutive Officer
- Christopher AkerExecutive Officer
- Denis DryginExecutive Officer
- Stelios PapadopoulosDirector
- David BaltimoreDirector
- Kathryn J. CollierDirector
- Jake R. NunnDirector
- William H. RastetterDirector
- Hugh RosenDirector
- Simos SimeonidisDirector
- Pascale WitzDirector
- Offering amount
- $34.5M
- Amount sold
- $19.4M
- Sales commissions
- $1.1M
- Placement agents
- H. C. Wainwright & Co., LLC
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$16.7MraisedMay 2019 · 21 investors · PharmaceuticalsRule 506(b)
▶$16.7MraisedMay 2019 · 21 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Joseph P. HaganExecutive Officer, Director
- Daniel R. ChevallardExecutive Officer
- Christopher AkerExecutive Officer
- David BaltimoreDirector
- Stelios PapadopoulosDirector
- William H. RastetterDirector
- Pascale WitzDirector
- Hugh RosenDirector
- Kathryn L. CollierDirector
- Offering amount
- $79.3M
- Amount sold
- $16.7M
- Sales commissions
- $2.3M
- Placement agents
- H.C. Wainwright Co.
- First sale
- May 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10MraisedFeb 2014 · 1 investors · BiotechnologyRule 506(b)
▶$10MraisedFeb 2014 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mark G. FolettaDirector
- John MaraganoreDirector
- Douglas E. WilliamsDirector
- William H. RastetterDirector
- David BaltimoreDirector
- Bruce L.A. CarterDirector
- B. Lynne ParshallDirector
- Neil GibsonExecutive Officer
- Stelios PapadopoulosDirector
- Kleanthis XanthopoulosExecutive Officer, Director
- Offering amount
- $10M
- Amount sold
- $10M
- First sale
- Feb 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $300K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- Who are Regulus Therapeutics Inc.'s investors?
- Regulus Therapeutics Inc.'s investors include New Enterprise Associates (NEA), SR One Capital Management.
- How much funding has Regulus Therapeutics Inc. raised?
- Regulus Therapeutics Inc. has disclosed $80.7M raised across 4 rounds.
- Where is Regulus Therapeutics Inc. headquartered?
- Regulus Therapeutics Inc. is headquartered in San Diego, US.